Saturday 17 October 2026
Export LXRX’s income statement to Excel — free account
Lexicon Pharmaceuticals, Inc.
LXRX Healthcare Biotechnology
Lexicon Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $49.8 million, up 60.2% from fiscal 2024. In the quarter to June 2026, revenue fell 97.6%, EPS fell 800.0%, free cash flow fell 154.1% and total debt fell 8.32%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
1.52
0.13
−7.88%
Follow LXRX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 3.40 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
1 | 2 | 1 | 7 | 1 | 3 | 2 | 2 | 5 | 4 |
Altman Z-Score |
(1.20) | (2.87) | (6.29) | (0.95) | (4.82) | (1.96) | (9.98) | (11.00) | (9.56) | (12.11) |
P/S ratio |
18.61 | 11.62 | 11.12 | 1.37 | 15.80 | 1,925.73 | 2,372.72 | 292.02 | 7.62 | 8.38 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 3.88 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(7.18) | (8.76) | (16.26) | (3.51) | (16.94) | (31.38) | (24.59) | (25.27) | (20.51) | (33.00) |
P/Operating CF |
(30.23) | (31.59) | (25.90) | (18.09) | (11.07) | (25.14) | (15.29) | (6.96) | (11.02) | (24.23) |
Beneish M-Score |
8.68 | (2.29) | (1.55) | 2.15 | (3.60) | (10.38) | (1.14) | 6.84 | 18.61 | (1.17) |
P/B ratio |
9.37 | 15.60 | 0.00 | 3.76 | 2.42 | 5.05 | 2.82 | 3.78 | 1.62 | 3.88 |
Price to Tangible BV |
24.79 | 0.00 | 0.00 | 8.34 | 3.39 | 8.31 | 4.54 | 7.24 | 2.34 | 6.63 |
EV/Sales |
15.52 | 10.91 | 12.46 | 1.29 | 9.96 | 1,642.30 | 1,736.13 | 234.53 | 3.23 | 7.54 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 2.83 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(7.00) | (5.39) | (5.30) | 3.64 | (1.67) | (5.62) | (2.72) | (1.74) | (0.56) | (5.53) |
EV/FCF |
(6.99) | (5.39) | (5.30) | 3.64 | (1.81) | (5.55) | (2.68) | (1.74) | (0.56) | (5.45) |
Quick Ratio |
2.15 | 2.99 | 4.52 | 5.02 | 3.26 | 3.92 | 5.97 | 5.42 | 5.34 | 4.73 |
Current Ratio |
2.17 | 3.05 | 4.72 | 5.17 | 3.37 | 4.02 | 6.08 | 5.60 | 5.44 | 4.88 |
Net Debt/EBITDA |
1.97 | 0.51 | (0.86) | (0.18) | 3.19 | 0.97 | 0.89 | 0.42 | 0.71 | 0.91 |
Debt/Assets |
21.33% | 56.28% | 86.23% | 58.70% | 6.01% | 1.66% | 25.67% | 43.37% | 33.61% | 29.19% |
Debt/Equity |
0.64 | 3.60 | (9.28) | 2.09 | 0.08 | 0.02 | 0.43 | 1.07 | 0.69 | 0.50 |
Asset Turnover |
0.14 | 0.20 | 0.18 | 0.92 | 0.08 | 0.00 | 0.00 | 0.01 | 0.12 | 0.21 |
Operating CF/Net income |
1.34 | 1.51 | 1.23 | 0.87 | 2.44 | 0.99 | 0.87 | 0.91 | 0.89 | 1.35 |
Capex/Depreciation |
(0.09) | (0.06) | (0.02) | (0.01) | 2.77 | (3.53) | (1.14) | (0.20) | (0.43) | 0.00 |
Interest Coverage |
(19.37) | (18.70) | (4.97) | 6.84 | (3.29) | (108.59) | (36.24) | (13.11) | (12.65) | (5.87) |
| (59.31%) | (109.00%) | (575.96%) | 286.97% | (42.84%) | (65.01%) | (88.37%) | (168.50%) | (167.66%) | (39.72%) | |
| (23.31%) | (26.97%) | (33.45%) | 37.08% | (18.85%) | (51.52%) | (61.56%) | (83.60%) | (75.93%) | (20.83%) | |
ROIC |
0.00% | (2,594.22%) | (110.26%) | 97.55% | (182.69%) | (186.85%) | (219.91%) | (475.14%) | (1,485.93%) | (46.81%) |
Return on Tangible Assets |
(61.82%) | (52.52%) | (79.08%) | 45.43% | (52.67%) | (129.11%) | (85.12%) | (120.50%) | (98.51%) | (60.73%) |
Average Days of Receivables |
34.50 | 19.21 | 34.21 | 64.07 | 6.01 | 17.15 | 73.53 | 306.19 | 40.79 | 17.47 |
Research and Development Expense of Revenue |
206.89% | 166.02% | 158.59% | 28.54% | 640.22% | 18,471.81% | 37,997.12% | 4,890.95% | 271.81% | 122.73% |
Selling, General and Administrative Expense of Revenue |
54.45% | 72.08% | 100.86% | 17.65% | 196.83% | 10,853.02% | 34,592.09% | 9,466.94% | 460.42% | 74.93% |
Intangible Assets out of Total Assets |
0.21 | 0.22 | 0.33 | 0.15 | 0.22 | 0.33 | 0.23 | 0.19 | 0.15 | 0.24 |
Share Based Compensation of Revenue |
9.40% | 10.33% | 18.50% | 4.41% | 55.32% | 3,549.33% | 8,287.77% | 1,191.03% | 43.43% | 25.13% |
Graham Net Nets |
0.03 | (0.04) | (0.20) | 0.08 | 0.29 | 0.11 | 0.19 | 0.11 | 0.40 | 0.06 |
Graham Number |
0.00 | 0.00 | 2.54 | 5.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(8.98%) | (11.47%) | (17.32%) | 29.40% | (16.08%) | (15.48%) | (30.65%) | (50.31%) | (86.49%) | (12.17%) |
Free Cash Flow Yield |
(11.92%) | (17.43%) | (21.16%) | 25.80% | (34.83%) | (15.38%) | (27.34%) | (46.18%) | (75.93%) | (16.50%) |
Revenue per Share |
0.76 | 0.87 | 0.60 | 3.03 | 0.22 | 0.00 | 0.00 | 0.01 | 0.10 | 0.14 |
Operating CF per Share |
(1.69) | (1.76) | (1.40) | 1.07 | (1.29) | (0.60) | (0.54) | (0.73) | (0.56) | (0.19) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.10 | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(1.69) | (1.76) | (1.41) | 1.07 | (1.19) | (0.61) | (0.54) | (0.73) | (0.56) | (0.19) |
Cash per Share |
3.34 | 2.95 | 1.51 | 2.56 | 1.37 | 0.60 | 0.83 | 0.77 | 0.74 | 0.27 |
Shareholders Equity per Share |
1.52 | 0.65 | (0.25) | 1.10 | 1.41 | 0.78 | 0.71 | 0.42 | 0.46 | 0.30 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.52 | 0.65 | (0.25) | 1.10 | 1.41 | 0.78 | 0.71 | 0.42 | 0.46 | 0.30 |
Free Cash Flow |
(175.86) | (185.62) | (148.70) | 113.74 | (132.04) | (88.24) | (90.18) | (162.37) | (179.81) | (67.85) |
Working Capital |
193.23 | 216.51 | 136.57 | 272.41 | 110.91 | 66.80 | 117.69 | 145.00 | 200.95 | 81.03 |
Capital Expenditures |
(0.23) | (0.23) | (0.09) | (0.07) | 10.93 | (1.22) | (1.33) | (0.47) | (1.03) | — |
Net Current Asset Value |
39.65 | (46.28) | (137.22) | 37.14 | 110.30 | 65.61 | 63.69 | 40.23 | 93.72 | 24.45 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 2.93 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | (0.46) | 4.10 | 9.54 | 0.39 | 0.03 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 3.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.13 | 0.23 | 0.32 | 0.36 | 13.38 | 0.29 | 0.56 | 1.17 | 0.96 | 1.25 |
Cash ROIC |
(29.05%) | (29.71%) | (39.27%) | 17.94% | (41.15%) | (43.55%) | (29.53%) | (44.77%) | (37.14%) | (26.32%) |
Accounts Receivable Turnover |
18.86 | 14.89 | 11.76 | 10.31 | 0.84 | 1.46 | 6.62 | 2.32 | 13.87 | 17.01 |
Accounts Payable Turnover |
0.00 | 0.04 | 0.10 | 0.27 | 0.22 | 0.00 | 0.04 | 0.01 | 0.04 | 0.03 |
Inventory Turnover |
— | 0.57 | 0.75 | 0.72 | 0.84 | — | 0.00 | 0.23 | 2.01 | 1.07 |
Average Days of Payables |
0.00 | 7,450.31 | 1,765.95 | 1,375.73 | 1,034.83 | 0.00 | 8,885.66 | 61,788.06 | 8,770.07 | 4,106.92 |
Days of Inventory on Hand |
— | 374.42 | 685.75 | 479.32 | 65.28 | — | 0.00 | 1,636.06 | 136.88 | 374.32 |
Average Receivables |
4.20 | 6.16 | 5.37 | 31.23 | 28.46 | 0.20 | 0.02 | 0.52 | 2.24 | 2.93 |
Average Payables |
36.30 | 45.82 | 25.41 | 12.12 | 8.82 | 7.31 | 9.77 | 12.39 | 14.60 | 8.94 |
Average Inventory |
— | 3.31 | 3.31 | 4.46 | 2.29 | — | — | 0.36 | 0.31 | 0.26 |
Average Assets |
563.79 | 456.08 | 360.34 | 350.93 | 310.75 | 170.35 | 165.60 | 211.86 | 263.92 | 241.70 |
Average Common Equity |
221.63 | 112.83 | 20.93 | 45.35 | 136.74 | 134.98 | 115.36 | 105.12 | 119.53 | 126.74 |
Columns are period end dates